Pentoxifylline, an analogue of theophylline and phosphodiestrase inhibitor is used in the treatment of peripheral vascular diseases. The objective of present investigation was to formulate and in-vitro characterize pentoxifylline loaded chewable tablets for the treatment of peripheral vascular disease with varying concentration of sodium starch glycolate (SSG) as super-disintegrent. The pentoxiphyline loaded chewable tablets were prepared by using wet granulation technique. Lactose and mannitol were used as diluents with different concentration of sodium starch glycolate (SSG) as super-disintegrate The in-vitro drug release profile was carried out in phosphate buffer phosphate buffer saline (PBS pH 6.8) at 37±0.1ºC using USP paddle type II. Prepared granules were subjected to precompression studies like angle of repose and compressibility indices. The compressed formulations were then evaluated for appearance, thickness, weight variation, hardness, friability, drug content uniformity, wetting time and disintegration time and in-vitro drug release profile. The results of all evaluation parameters were within acceptable limits. From the disintegration studies, it was observed that the formulation containing 4.0% w/w of sodium starch glycolate showed minimum disintegration time than other formulations. The optimised formulation showed 97.82% in-vitro drug release in 30 minutes.A significant difference was observed in in-vitro drug release due to varying concentration of superdisintegrant as well as diluents. Thus, it can be concluded that Pentoxifylline loaded chewable tablet can be a potential dosage form for the therapy of peripheral vascular diseases.
